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Abstract
Genome-wide association studies (GWAS) have been successful in finding associations between specific genetic variants
and cancer susceptibility in human populations. These studies have identified a range of highly statistically significant
associations between single nucleotide polymorphisms (SNPs) and susceptibility to development of a range of human
tumors. However, the effect of each SNP in isolation is very small, and all of the SNPs combined only account for a relatively
minor proportion of the total genetic risk (5–10%). There is therefore a major requirement for alternative routes to the
discovery of genetic risk factors for cancer. We have previously shown using mouse models that chromosomal regions
harboring susceptibility genes identified by linkage analysis frequently exhibit allele-specific genetic alterations in tumors.
We demonstrate here that the Fbxw7 gene, a commonly mutated gene in a wide range of mouse and human cancers,
shows allele-specific deletions in mouse lymphomas and skin tumors. Lymphomas from three different F1 hybrids show
100% allele-specificity in the patterns of allelic loss. Parental alleles from 129/Sv or Spretus/Gla mice are lost in tumors from
F1 hybrids with C57BL/6 animals, due to the presence of a specific non-synonymous coding sequence polymorphism at the
N-terminal portion of the gene. A specific genetic test of association between this SNP and lymphoma susceptibility in
interspecific backcross mice showed a significant linkage (p = 0.001), but only in animals with a functional p53 gene. These
data therefore identify Fbxw7 as a p53-dependent tumor susceptibility gene. Increased p53-dependent tumor susceptibility
and allele-specific losses were also seen in a mouse skin model of skin tumor development. We propose that analysis of
preferential allelic imbalances in tumors may provide an efficient means of uncovering genetic variants that affect mouse
and human tumor susceptibility.
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Introduction
Susceptibility to cancer development is consequence of a
combination of genetic and environmental factors. Whereas a
wide range of environmental agents may contribute to cancer
development, the genetic component of risk is difficult to dissect
[1]. Genetic risk factors for cancer are either in the high
penetrance category, such as mutations in BRCA1/2 that cause
familial breast and ovarian cancers, or are classified as low
penetrance variants that work additively or in complex combina-
tions to increase risk [1,2]. Relatively little is known about the
genes in this latter category, which are nevertheless likely to be
very important determinants of the developmental risk of many
cancer types [2,3]. Present approaches to the detection of low
penetrance tumor susceptibility alleles in humans involve associ-
ation studies using DNA samples from hundreds or thousands of
cancer patients, and an equal number of well-matched controls.
Such studies are plagued by confounding factors such as
population heterogeneity, weak effects, and genetic interactions,
and require very large numbers of cases and controls to reach
statistical significance [4–6]. For many complex trait diseases,
including cancer, the total number of significant SNP associations
detected can only account for a very small proportion of the total
genetic risk [7], leading to considerable discussion of the best ways
to discover the majority of disease-causing alleles in the human
population.
Mouse models offer an important alternative approach to the
study of cancer susceptibility. Studies on mice have revealed that
tumor predisposition in different strains is controlled by multiple
loci that exhibit complex genetic interactions [8,9]. Importantly, in
these mouse crosses only two alleles at each locus are segregating
in the population, and the large differences in susceptibility are
therefore due to combinations of common alleles. However, the
resolution of mapping studies, based on linkage analysis involving
inbred strains alone, is poor [1,3]. Analysis of somatic events in
tumors could provide more high resolution information from
relatively smaller numbers of samples [10,11], due to the fact that
genetic instability in tumors results in specific genetic aberrations
leading to copy number gains or losses of important cancer genes.
Indeed, analysis of somatic deletions was instrumental in
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identification of the causal genes for hereditary cancer syndromes
such as Li-Fraumeni syndrome and retinoblastoma. Predisposition
to tumor development caused by a germline mutation was
accompanied by tumor-specific loss of the wild type allele
(TRP53 and RB respectively), thus establishing a precedent for
use of somatic genetic alterations for identification of germline
tumor susceptibility genes [12,13]. The information obtained from
somatic events in tumors combined with linkage analysis could
provide the opportunity to obtain more high resolution informa-
tion from relatively smaller numbers of samples. Thus, fine
mapping of somatic recombination events, deletions and ampli-
fications, together with genotyping to detect preferential allelic
imbalance, could offer important clues to the localization of
polymorphisms of low penetrance genes that influence cancer
susceptibility [10,11,14].
We previously identified the Fbxw7 gene (also known as hCDC4,
Fbw7 and hAGO) as a tumor suppressor gene for radiation-induced
lymphoma [15,16]. The Fbxw7 gene encodes an F-box protein,
essential for the ubiquitination of different oncoproteins, including
c-Myc [17,18], c-Jun [19], cyclin E [20–22], different members of
the Notch family [23–25], Aurora-A [15,26], and mTor [27,28].
FBXW7 gene mutations have been found in cancers from a wide
spectrum of human tissues, such as bile duct, the haematopoietic
system, bone, brain, breast, colon, endometrium, stomach, lung,
ovary, pancreas, prostate, and head and neck [29,30]. The overall
frequency of point mutations in FBXW7 in human cancers is about
6% [31]. Deletion of the Fbxw7 gene in mice leads to embryonic
lethality, but heterozygous mice develop normally [32,33].
Although they do not develop spontaneous tumors, radiation
exposure gives rise to different types of tumors, including a range
of epithelial cancers [15].
Since Fbxw7 is frequently mutated or deleted in a large
proportion of lymphomas from p53 heterozygous mice [15], we
first analyzed the possibility that these deletions may preferentially
involve one parental allele. Here we demonstrate that a strain-
dependent polymorphism in the N-terminus of Fbxw7 causes
100% selectivity in patterns of alleleic loss in mouse lymphomas.
Genetic linkage studies confirmed that this polymorphism confers
increased risk of tumor development in a p53-dependent manner.
Extension of this approach to human samples may identify a
proportion of the genetic variants that affect cancer risk, but are
not detected by standard linkage of genetic association studies.
Results
Allele-specific loss of Fbxw7 in radiation-induced mouse
Lymphomas
We have previously proposed that it may be possible to identify
germline polymorphisms that influence susceptibility by analysis of
allele-specific deletions or amplifications in mouse or human
tumors [10,11]. Thus, we carried out a detailed analysis of the
directionality of allele loss of Fbxw7 in lymphomas from a series of
different p53+/2 F1 hybrid mice. In contrast to tumors derived
from 129/Sv6Mus spretus (Spretus/Gla) hybrids, which showed 50%
loss of markers on each parental chromosome 3 (Fig. 1A), tumors
derived from F1 hybrids between C57BL/6 and Mus spretus, or
between C57BL/6 and 129/Sv, showed consistent loss of the Mus
spretus or 129/Sv alleles respectively (Fig. 1A). Although these
examples of chromosomal imbalance involve large regions of
mouse chromosome 3 that include the region containing Fbxw7,
our previous studies demonstrated that Fbxw7 was indeed the
driver gene for these losses, since tumors exhibited intragenic
Figure 1. Detection of allele-specific loss of Fbxw7 gene in radiation-induced thymic lymphomas. (A) PCR analysis at the Fbxw7 locus:
Tumors derived from F1 hybrids between C57BL/6 and 129/Sv, or C57BL/6 and Mus spretus, showed consistent loss of the 129/Sv or Mus spretus alleles,
respectively; whereas tumors derived from 129/Sv and Mus spretus hybrids showed loss of either 129/Sv or Spretus alleles at the same frequency. (B)
Sequence analysis showing the polymorphism in Fbxw7 between C57BL/6 (B6) and Mus spretus (Spr). (C) Comparison of the amino acid sequences at
the Fbxw7a polymorphic region in Mus spretus, 129/Sv, C57BL/6, FVB/N, NIH/Ola strain by sequencing.
doi:10.1371/journal.pone.0031301.g001
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Fbxw7 deletions or mutations, and lymphomas from p53+/
2Fbxw7+/2 mice did not show any evidence of significant
deletions on this chromosome [15]. These data suggested that
129/Sv and Spretus/Gla may carry similar haplotypes in the Fbxw7
region, while C57BL/6J should carry a different sequence.
Sequence analysis demonstrated that Spretus/Gla and 129/sv
strains share a non-synonymous coding sequence polymorphism
at position 61 (GAC) that encodes Aspartic acid whereas in
C57BL/6 mice there is an Asparagine residue (AAC) leading to the
disappearance of a negative charge (Fig. 1B). Additional
sequencing of other strains showed that this polymorphism
segregates in many common laboratory strains of mice (Fig. 1C,
Table 1).
Asp61Asn polymorphism in Fbxw7 is associated with
susceptibility to development of radiation-induced
lymphoma
Having found a common allele-specific deletion involving Fbxw7
on chromosome 3, we then asked whether this polymorphism is
associated with altered susceptibility to development of radiation-
induced lymphomas. We previously carried out a cross between
outbred Spretus/Gla and p532/2 mice of a mixed C57BL/6 and
129/Sv genetic background (1296B6 mice). These interspecific F1
hybrid p53+/2 animals were backcrossed to the 129/B6 p532/2
mice to generate a backcross population (n = 168) of which
approximately half of the animals were p53+/2, while the
remainder were homozygous for the p53 null allele (p532/2)
[15]. Since all 3 Fbxw7 alleles were segregating within this
population, we tested the possibility of association between
lymphoma development and the presence of the candidate
susceptibility SNP in Fbxw7. While there was no detectable
influence of the Asp61Asn polymorphism in Fbxw7 on lymphoma
development in p532/2 mice (Fig. 2B), a significant effect was
detected at the same SNP in radiation-induced lymphomas from
p53+/2 mice (Fig. 2A). The result is in agreement with the
observation that the tumor suppressor activity of Fbxw7 is also p53-
dependent [15,16]. To our knowledge, this is the first example of a
natural genetic variant that influences tumor development in a
p53-dependent manner.
Fbxw7 Participates in Skin Tumor Progression
Loss or mutation of FBXW7 has been identified in a wide range
of human tumors of both mesenchymal and epithelial origin [29].
To clarify the role of Fbxw7 in epithelial cancer development, we
investigated the consequences of Fbxw7 deficiency in the DMBA/
TPA mouse model of skin cancer development. In this model, skin
tumors are initiated by treatment with a single dose of the
carcinogen DMBA, which induces H-ras gene mutations in target
cells. Subsequent promotion of these cells by treatment with TPA
results in formation of benign papillomas, a subset of which
undergoes malignant progression to carcinomas. Since complete
loss of Fbxw7 is lethal in mice, we examined the effects of partial
Fbxw7 deficiency on skin tumor development, both in wild type
mice and in animals lacking one functional copy of the p53 gene.
Groups of 19 Fbxw7+/+, 28 Fbxw7+/2, 32 p53+/2 and 34 p53+/
2Fbxw7+/2 mice were initiated by a single dose of DMBA and
promoted twice weekly with TPA. Mice that were wild type at the
p53 locus showed no effect of reduced Fbxw7 gene dosage on
papilloma number (Fig. 3A). However there was a strong and
statistically significant increase in the number of papillomas in
p53+/2Fbxw7+/2 mice compared with p53+/2 mice (Fig. 3B).
We conclude that Fbxw7 is an important regulator of skin tumor
progression, and that a partial germline deficiency causes
increased susceptibility to papilloma development, particularly in
the context of a reduced gene dosage for p53. These data extend
and support the conclusion above that Fbxw7 is an important
tumor suppressor gene that interacts strongly with the p53
pathway.
We next investigated the possibility that allele-specific deletions
in Fbxw7 locus may occur in skin tumors. Due to normal tissue
contamination, it is hard to detect allele-specific change in skin
tumors by regular PCR described in lymphoma studies. Thus we
designed TaqMan probes specific for Fbxw7 polymorphisms
discovered above. Gene copy number changes at the Fbxw7 locus
were examined by quantitative PCR (TaqMan) analysis of skin
tumors from interspecific backcross mice derived by crossing male
Spretus/Gla with female mice of the NIH/O strain that carry the G
and A alleles respectively (see Table 1). Female F1 hybrid mice
generated from this cross were backcrossed to the parental NIH/O
strain to generate a backcross population (NIHBX) as previously
described [34,35]. Fbxw7 deletions were detected in some
papillomas and in the majority of the carcinomas studied
(Fig. 4A). Analysis of the pattern of allele-specific losses in these
tumors indicated that the preference was overwhelmingly for loss
of the Fbxw7 allele inherited from the Mus spretus parent. These
data indicate that loss of Fbxw7 is an important event in skin
cancer progression, and demonstrate that the strain-specific
polymorphism affects the directionality of the deletion in the
same manner as was seen for lymphomas.
In the lymphoma model described above, the presence of the
G/A allele was linked to the allele-specific deletions and also, by
SNP association analysis, to susceptibility to lymphoma develop-
ment. We investigated the possibility that allele-specific losses of
Fbxw7 in the NIHBX population may also predict linkage to a skin
tumor susceptibility locus in the region containing the Fbxw7 gene
on chromosome 3. Interestingly, although allele-specific deletions
were clearly seen in tumors from this backcross, no obvious linkage
was detected to markers near the Fbxw7 locus (Fig. 4B). We
conclude that in this skin model, analysis of preferential allelic
imbalance in tumors leads to detection of a germline susceptibility
locus that is not detected by standard linkage analysis.
Discussion
The identification of low penetrance cancer susceptibility genes
is a major challenge, and fraught with difficulties in standard
human population studies. In this work we have established
Table 1. Distribution of Fbxw7 alleles among different mouse
strains by sequencing analysis.
G allele A allele
Strains Spretus/EiJ BABL/C C57BL/6J RIII/DmM
Spretus/Gla AKR/J SWR A/WySnJ
Spretus/Pas Cast/Ei CBA/J NOD/LtJ
129/Sv C3H/He Non/Ltj
LG/J A/J SM/J
Lp/J C57BR/cdJ
DBA/1J NIH/O
DBA/2J FVB/N
129/REJ SJL/J
PL/J SenCarC/PtJ
doi:10.1371/journal.pone.0031301.t001
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evidence that supports the approach of studying somatic mutation
events within the tumors, in combination with linkage analysis, to
identify polymorphic allelic variants that have cell-autonomous
effects on tumor development. Analysis of allele-specific deletions
of Fbxw7 locus in mouse lymphomas showed that the pattern in
three different sets of F1 hybrid was 100% specific: the allele
contributed by the C57BL/6 parent was selectively retained, while
alleles from either Mus spretus or 129/Sv were preferentially lost,
in lymphomas from the respective F1 hybrid animals. An
association study in a backcross in which all 3 alleles were
segregating confirmed that the AAC (Asn) allele inherited from the
C57BL/6 parent conferred greater risk of lymphoma than the
GAC (Asp) allele from either 129/Sv or Mus spretus. An important
conclusion is that while the genetic effect of the polymorphism on
overall cancer risk is small and this variant is clearly in the ‘‘low
penetrance’ category, the effect shows 100% penetrance in the
pattern of allele-specific loss of heterozygosity in lymphomas.
Application of this approach to human cancers may therefore
identify genetic variants that only have very small and possibly
undetectable effects on cancer risk in GWAS, but have strong
effects on somatic genetic changes.
Our results on the skin tumor model lend strong support to the
conclusion that Fbxw7 variants contribute to cancer risk. In this
model, loss of heterozygosity at the Fbxw7 gene is specific for the
Spretus allele, and no examples were seen of loss of the parental
NIH/O (AAC) allele. In addition, germline deletion of one copy of
Fbxw7 clearly increased skin tumor susceptibility, particularly in
the context of p53 deletion. Nevertheless, in the same backcross
population in which the allele-specific losses were seen, no
evidence was detected of a significant germline skin tumor
susceptibility gene at this locus using a range of markers on
mouse chromosome 3. The reasons for this observation are
unclear, but it is possible that additional germline susceptibility or
resistance alleles for skin cancer map within the same linkage
region as Fbxw7. If these act in the opposite direction, the effect
due to susceptibility through the Fbxw7 AAC allele may be masked
by the opposing genetic effects of these linked variants, as discussed
previously [1]. The results of linkage analysis may therefore
depend on the tissue and tumor type under investigation, where in
some cases closely linked genetic variants that act in opposite
directions may confound detection of susceptibility alleles. Similar
Figure 2. Fbxw7 is a polymorphic genetic modifier of radiation-induced lymphoma development. Animals from a backcross between
Mus spretus and 1296B6 p53-deficient mice were genotyped at the Fbxw7 polymorphic locus and monitored for lymphoma development after 4 Gy
whole body c-radiation exposure (A) Lymphoma development in p53+/2 mice, and (B) in p532/2 mice, respectively.
doi:10.1371/journal.pone.0031301.g002
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tissue-specific effects may underlie the differential effect of p53
status on germline deletion of Fbxw7.
It has been reported that monoallelic deletion of Fbxw7 in
different tumor systems, in human and mouse, is a frequent event
during cancer progression [15,29], and that Fbxw7 acts as a
haploinsufficient tumor suppressor gene[15,29]. In the light of
these results on mouse models of cancer, it is possible that specific
genetic variants in human FBXW7, or indeed of other common
human tumor suppressors, may also affect the patterns of allelic
losses in tumors. Such changes may be more difficult to detect in
human tumors than are allele-specific gene amplifications [10]
which occur over a wider range of copy number changes and are
less subject to confounding by the presence of contaminating
normals cell that increase the signal-noise ratio. Nevertheless,
tumor microdissection in combination with genome-wide analysis
of allelic imbalances may reveal new opportunities to detect
germline variants that influence cancer risk.
In preliminary studies we have been unable to detect any effect
of the specific C57BL/6 or Mus spretus alleles on intracellular
localization of epitope tagged Fbxw7 proteins or any reproducible
differences in protein stability (data not shown). While a human
non-synonymous coding sequence polymorphism has been found
in the same region of the human gene, this is only seen at low
frequency in populations of African descent (rs6842544:
AGARGGA) (http://www.ncbi.nlm.nih.gov/snp). Further studies
will be required to investigate possible allele-specific loss or
retention of this allele in tumors from heterozygous patients.
Elucidation of the mechanisms by which this and other Fbxw7
genetic variants act may allow us in future studies to recognize
patients who are at high risk of cancer development, or who may
be more likely to respond to therapies targeted at this pathway.
The recent identification of mTOR as a downstream target of
Fbxw7 [27,28] suggests that germline or somatic changes may
affect tumor responses to known inhibitors of the mTOR pathway
Figure 3. Skin cancer induction by DMBA-TPA protocol in Fbxw7 deficient mice. (A) Loss of a single copy of Fbxw7 does not significantly
affect papilloma development: Average of papillomas in Fbxw7+/2 and wild type mice. (B) Loss of Fbxw7 increases susceptibility to papilloma
development in a p53-heterozygous background. There were significant differences in the average of papilloma development between p53+/
2Fbxw7+/+ and p53+/2Fbxw7+/2 mice (Mann-Whitney test).
doi:10.1371/journal.pone.0031301.g003
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such as rapamycin, and such investigations are presently in
progress in this laboratory.
Materials and Methods
Mouse breeding and tumor induction
Skin Cancer. The mice used for this study have been
described previously for skin tumor susceptibility [11,34,35]; in
short, female interspecific F1 hybrid mice between NIH/Ola and
Spretus/Gla were crossed with male NIH/Ola to generate the F1
backcross mice (NIH/Ola6Spretus/Gla)6NIH/Ola. Additionally,
Fbxw7+/2 knockout mice, generated at Dr. Nakayama’s
laboratory [32], were crossed with P53 knockout heterozygous
mice. P53 and Fbxw7 single- or double-heterozygous knockout
mice were generated by crossing Fbxw7+/2 with p53+/2 mice.
The F1 backcross mice, together with wild type, Fbxw7+/2,
P53+/2 and double heterozygous Fbxw7+/2P53+/2 mice were
treated with DMBA and 12-O-tetradecanoylphorbol-13-acetate
according to the standard two-stage carcinogenesis protocol [34].
Radiation-induced Lymphoma. This cohort of mice was
described before for radiation-induced induced lymphoma
susceptibility [15,36]. Briefly, F1 hybrid mice were generated by
crossing females p532/2 129/B6 with males p53 wild type
Spretus/Gla, and F1 backcross mice were obtained by mating the
female F1 hybrids with male p532/2 129/B6 mice. The 5-week-
old 129/Sv, F1 and F1 backcross mice were exposed to a single
dose of 4 Gy whole-body irradiation and observed daily until they
were sick, then sacrificed and autopsied.
Mice were bred and treated under University of California at
San Francisco (UCSF) Laboratory Animal Resource Center
(LARC) regulations.
Allele specific LOH determination
PCR Analysis. For DNA preparation, tumors were ground
into a fine powder in liquid nitrogen. DNA was isolated using
standard phenol/chloroform extraction following over-night 55uC
incubation with Proteinase-K. All tumor DNA samples were
Figure 4. Allele-specific change and linkage analysis of Fbxw7 locus in skin tumors. (A) Analysis of allele-specific Fbxw7 gene copy number
by QPCR in primary skin tumors. The Fbxw7 allele from the Mus spretus parent was deleted in early stages of skin cancer development. Samples 1, 6
and 7 are papillomas; samples 13 and 14 are spindle carcinomas; all the rest are squamous carcinomas. DDCT less than20.5 indicates loss of the Mus
Spretus allele. (B) LOD scores for number of papillomas on Chromosome 3 were generated by R/QTL.
doi:10.1371/journal.pone.0031301.g004
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examined together with normal DNA from the same mice, to take
account of variation in Fbxw7 alleles. Tumor and corresponding
normal DNA was used for LOH studies with microsatellite
markers at the Fbxw7 locus [15]. PCR amplification was
performed in 20-mL volume containing 16 PCR buffer (Bioline),
200 mM of each dNTP (Pharmacia), 6.6 mM of each primer
(Qiagen Operon), 1.5 mM MgCl2, 2 units of Taq polymerase
(Bioline), and 80 ng of DNA. Amplifications were initially
denatured for 3 min at 94uC, followed by 35 cycles of 30 sec at
94uC, 30 sec at 55uC or 52uC, and 30 sec at 72uC. PCR products
were electrophoresed in 4% (3% NuSieve/1% normal) agarose gel
and visualized by ethidium bromide staining.
Quantitative Real Time PCR (QPCR) Analysis. Primers
and TaqMan probes were designed using the ABI Primer Express
Software (version 1.5). The absence of non-specific amplification
was confirmed by analyzing the PCR amplification by 3% agarose
gel electrophoresis and ethidium bromide staining. The sequences
were as follows: Fbxw7 forward primer: GCGCGGAA-
TGGTGAACTT; Fbxw7 reverse primer: CGTTCTGGTCTC-
CAGGCCT; probe for Fbxw7-GAC allele: 59-FAM-
TGGGTGCAGACCCTA-MGB-39; probe for Fbxw7-AAC
allele: 59-VIC- TGGGTGCAAACCCTA -MGB-39. The probe
for the detection of amplified products was labeled with 6-
carboxifluorescein (FAM) in the 59end, all the reporters were
quenched by 6-carboxy-tetramethyl-rhodamine (TAMRA)
conjugated at the 39end. All probes were purchased in Applied
Biosystems. PCRs for each sample were carried out in triplicate and
repeated at least twice in 50 uL volume consisting in: 25 uL
TaqMan 26 PCR Mater Mix (Applied Biosystems), 100 nM
TaqMan probe, forward and reverse primers (100 uM). A master
mix of the components including the equivalent of 125 ng of DNA
per well (5 uL at 25 ng/uL) was made and aliquoted into a 96-well
optical plate (Applied Biosystems). PCRs were performed according
to the thermal profile: 1 cycle 50uC 2 min, 1 cycle 95uC 10 min, 40
cycles 95uC 15 sec and 60uC 1 min. For quantification of gene
relative copy number, we used comparative Ct method [37,38].
The Ct values for each set of triplicates were averaged. For Fbxw7
copy number |DDCt|.0.5 were considered to be losses.
Statistical and linkage analysis
The Kaplan–Meier method was used to compare the tumor
development after irradiation of mice carrying different alleles of
Fbxw7, and the Mann-Whitney test for comparing number of
papillomas between different genotypes of mice. Statistical analysis
was performed using SPSS version 12.0 (SPSS, Chicago, IL).
Linkage analysis was carried out using R/QTL.
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